Nevro Pre-Tax Profit Margin 2013-2022 | NVRO
Nevro pre-tax profit margin from 2013 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Nevro Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2022-09-30 |
$0.40B |
$-0.01B |
-1.77% |
| 2022-06-30 |
$0.39B |
$-0.14B |
-35.82% |
| 2022-03-31 |
$0.39B |
$-0.14B |
-34.97% |
| 2021-12-31 |
$0.39B |
$-0.13B |
-33.59% |
| 2021-09-30 |
$0.39B |
$-0.11B |
-27.16% |
| 2021-06-30 |
$0.41B |
$-0.07B |
-16.38% |
| 2021-03-31 |
$0.36B |
$-0.09B |
-23.97% |
| 2020-12-31 |
$0.36B |
$-0.08B |
-22.99% |
| 2020-09-30 |
$0.37B |
$-0.09B |
-24.38% |
| 2020-06-30 |
$0.36B |
$-0.10B |
-26.89% |
| 2020-03-31 |
$0.40B |
$-0.08B |
-21.01% |
| 2019-12-31 |
$0.39B |
$-0.10B |
-26.15% |
| 2019-09-30 |
$0.38B |
$-0.10B |
-25.78% |
| 2019-06-30 |
$0.38B |
$-0.09B |
-24.47% |
| 2019-03-31 |
$0.38B |
$-0.08B |
-19.63% |
| 2018-12-31 |
$0.39B |
$-0.05B |
-12.37% |
| 2018-09-30 |
$0.38B |
$-0.04B |
-11.11% |
| 2018-06-30 |
$0.36B |
$-0.04B |
-10.16% |
| 2018-03-31 |
$0.35B |
$-0.04B |
-10.98% |
| 2017-12-31 |
$0.33B |
$-0.04B |
-10.74% |
| 2017-09-30 |
$0.30B |
$-0.04B |
-13.38% |
| 2017-06-30 |
$0.28B |
$-0.04B |
-13.31% |
| 2017-03-31 |
$0.26B |
$-0.04B |
-13.73% |
| 2016-12-31 |
$0.23B |
$-0.03B |
-13.10% |
| 2016-09-30 |
$0.19B |
$-0.04B |
-18.32% |
| 2016-06-30 |
$0.15B |
$-0.05B |
-35.17% |
| 2016-03-31 |
$0.10B |
$-0.06B |
-61.39% |
| 2015-12-31 |
$0.07B |
$-0.07B |
-97.10% |
| 2015-09-30 |
$0.05B |
$-0.06B |
-132.61% |
| 2015-06-30 |
$0.04B |
$-0.05B |
-125.00% |
| 2015-03-31 |
$0.04B |
$-0.04B |
-100.00% |
| 2014-12-31 |
$0.03B |
$-0.03B |
-88.24% |
| 2014-06-30 |
$0.02B |
$-0.02B |
-90.48% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$1.410B |
$0.387B |
|
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
|
